| Previous Close | 23.65 |
| Open | 23.2 |
| Day High | 25.25 |
| Day Low | 22.76 |
| 52-Week High | 33.63 |
| 52-Week Low | 17.79 |
| Volume | 28,890 |
| Average Volume | 97,987 |
| Market Cap | 44.4M |
| PE | -38.15 |
| EPS | -0.65 |
| Moving Average 50 Days | 23.13 |
| Moving Average 200 Days | 24.83 |
| Change | 1.15 |
Precipio Announces Publication of a Joint Study with Memorial Sloan-Kettering Cancer Center Highlighting Its Cutting-Edge Bloodhound BCR::ABL1 Assay
GlobeNewswire Inc.
Mar 10, 2026 1:00 PM GMT
This is the only assay available on the market that delivers full quantification of all four clinically relevant BCR::ABL1 isoformsNEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRP
Precipio 2025 (Unaudited) Revenues Grew to $24.0M, a 30% Increase Year-Over-Year
GlobeNewswire Inc.
Feb 25, 2026 2:30 PM GMT
In Q4-2025 the Company generated ~$400K in Operating Cash Flow, and Adjusted EBITDA of close to $1MNEW HAVEN, Conn., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces some preliminary (u
Precipio Takes Major Steps Toward a Clean Balance Sheet
GlobeNewswire Inc.
Jan 15, 2026 2:00 PM GMT
Less than $80,000 of long-term debt, and 10,000 vendor warrants remain outstandingNEW HAVEN, Conn., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has made major strides in cleaning up its balan